Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)
Standard Dosed Alectinib Versus Therapeutic Drug Monitoring Guided Alectinib Dosing
Sponsor: Amsterdam University Medical Center
A PHASE4 clinical study on Anaplastic Lymphoma Kinase Gene Mutation and Anaplastic Lymphoma Kinase Gene Translocation, this trial is actively recruiting participants. The trial is conducted by Amsterdam University Medical Center and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Mar 2023 — Jun 2024 [monthly]
Recruiting PHASE4
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE4
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amsterdam University Medical Center
- Erasmus Medical Center
- Leiden University Medical Center
- Maastricht University Medical Center
- Radboud University Medical Center
- The Netherlands Cancer Institute
- University Medical Center Groningen
For direct contact, visit the study record on ClinicalTrials.gov .